Market Closed -
Australian S.E.
11:40:14 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.51
AUD
|
0.00%
|
|
-16.39%
|
+148.78%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
14.73
|
13.5
|
69.21
|
38.61
|
38.5
|
24.06
|
Enterprise Value (EV)
1 |
8.445
|
9.935
|
62.52
|
38.45
|
28.95
|
22.03
|
P/E ratio
|
-3.3
x
|
-4.67
x
|
-13.4
x
|
-6.06
x
|
-3.37
x
|
-1.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.4
x
|
9.33
x
|
29.6
x
|
8.7
x
|
5.96
x
|
2.68
x
|
EV / Revenue
|
9.99
x
|
6.86
x
|
26.7
x
|
8.66
x
|
4.48
x
|
2.45
x
|
EV / EBITDA
|
-2.55
x
|
-3.45
x
|
-13.7
x
|
-5.93
x
|
-2.76
x
|
-1.59
x
|
EV / FCF
|
-4.3
x
|
-6.06
x
|
-19.9
x
|
-9.1
x
|
-2.91
x
|
-2.9
x
|
FCF Yield
|
-23.2%
|
-16.5%
|
-5.03%
|
-11%
|
-34.4%
|
-34.5%
|
Price to Book
|
2.15
x
|
3.21
x
|
8.92
x
|
26.3
x
|
2.67
x
|
4.03
x
|
Nbr of stocks (in thousands)
|
1,55,049
|
1,58,799
|
1,97,749
|
1,97,999
|
3,20,874
|
3,88,059
|
Reference price
2 |
0.0950
|
0.0850
|
0.3500
|
0.1950
|
0.1200
|
0.0620
|
Announcement Date
|
30/08/18
|
29/08/19
|
26/08/20
|
15/08/21
|
28/08/22
|
29/08/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.8453
|
1.447
|
2.341
|
4.44
|
6.466
|
8.984
|
EBITDA
1 |
-3.313
|
-2.882
|
-4.576
|
-6.479
|
-10.49
|
-13.84
|
EBIT
1 |
-3.32
|
-2.886
|
-4.577
|
-6.488
|
-10.49
|
-13.84
|
Operating Margin
|
-392.73%
|
-199.41%
|
-195.54%
|
-146.15%
|
-162.25%
|
-154.05%
|
Earnings before Tax (EBT)
1 |
-3.32
|
-2.886
|
-4.494
|
-6.372
|
-10.49
|
-13.8
|
Net income
1 |
-3.32
|
-2.886
|
-4.494
|
-6.372
|
-10.49
|
-13.8
|
Net margin
|
-392.73%
|
-199.41%
|
-191.98%
|
-143.52%
|
-162.25%
|
-153.64%
|
EPS
2 |
-0.0288
|
-0.0182
|
-0.0262
|
-0.0322
|
-0.0356
|
-0.0424
|
Free Cash Flow
1 |
-1.962
|
-1.639
|
-3.148
|
-4.228
|
-9.964
|
-7.604
|
FCF margin
|
-232.16%
|
-113.22%
|
-134.47%
|
-95.22%
|
-154.1%
|
-84.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/08/18
|
29/08/19
|
26/08/20
|
15/08/21
|
28/08/22
|
29/08/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
6.28
|
3.56
|
6.69
|
0.16
|
9.56
|
2.03
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.96
|
-1.64
|
-3.15
|
-4.23
|
-9.96
|
-7.6
|
ROE (net income / shareholders' equity)
|
-70%
|
-52.2%
|
-75.1%
|
-138%
|
-132%
|
-135%
|
ROA (Net income/ Total Assets)
|
-40.9%
|
-29.6%
|
-37.3%
|
-40.9%
|
-50.6%
|
-50.5%
|
Assets
1 |
8.109
|
9.764
|
12.04
|
15.56
|
20.73
|
27.33
|
Book Value Per Share
2 |
0.0400
|
0.0300
|
0.0400
|
0.0100
|
0.0400
|
0.0200
|
Cash Flow per Share
2 |
0.0400
|
0.0200
|
0.0400
|
0.0300
|
0.0300
|
0.0200
|
Capex
1 |
0
|
0.01
|
-
|
0.01
|
0.01
|
0
|
Capex / Sales
|
0.42%
|
0.48%
|
-
|
0.22%
|
0.16%
|
0.03%
|
Announcement Date
|
30/08/18
|
29/08/19
|
26/08/20
|
15/08/21
|
28/08/22
|
29/08/23
|
|
1st Jan change
|
Capi.
|
---|
| +148.78% | 19Cr | | +38.65% | 3.91TCr | | -8.95% | 3.88TCr | | +26.91% | 3.12TCr | | +10.78% | 2.59TCr | | -13.50% | 2.58TCr | | +44.00% | 1.41TCr | | +33.36% | 1.31TCr | | -7.97% | 1.13TCr | | -13.17% | 1.07TCr |
Other Biotechnology & Medical Research
|